Original Research Paper

Volume - 14 | Issue - 08 | August - 2024 | PRINT ISSN No. 2249 - 555X | DOI : 10.36106/ijar

Pharmacy

ANGINA PECTORIS: CURRENT UNDERSTANDING AND FUTURE PERSPECTIVES

Amrit Paul*	Asst Prof, Mata Gujri College of Pharmacy, Kishanganj, Bihar-855107 *Corresponding Author
Jagjot Gautam	Lecturer, Mata Gujri College of Pharmacy, Kishanganj, Bihar-855107
Shyamsundar Kumar	Student, Mata Gujri College of Pharmacy, Kishanganj, Bihar-855107
Aditya Raj	Student, Mata Gujri College of Pharmacy, Kishanganj, Bihar-855107

ABSTRACT Angina pectoris, or chronic chest pain or discomfort, is a typical sign of coronary artery disease, pointing to underlying myocardial ischemia. This study offers a thorough examination of the pathogenesis, clinical presentation, diagnostic evaluation, and upper management of angina. Among the primary objectives are elucidating the underlying causes of angina, outlining diagnostic methods, evaluating the effectiveness of treatment, and exploring new possibilities in research. Pharmacological therapies, lifestyle modifications, invasive procedures like coronary artery bypass grafting and angioplasty, and stress testing are examples of diagnostic modalities that aid in precise diagnosis and risk assessment. The main path physiological mechanisms are atherosclerosis and coronary artery disease, which are exacerbated by risk factors like smoking, hypertension, and hyperlipidemia. This review summarises the most recent research to help doctors optimise patient care and reduce the burden of angina-related morbidity and mortality. Recent developments include the identification of microvascular angina, precision medicine techniques, and the development of novel treatments aimed at the pathophysiology of angina. Future research directions include understanding gender variations, investigating new biomarkers, and examining lifestyle changes to improve angina treatment and cardiovascular outcomes.

KEYWORDS : Angina, Coronary artery disease, Chest pain,Myocardial ischemia, Hyperlipidemia, Microvascular angina, Coronary angiography, Angioplasty

INTRODUCTION

The hallmark of angina pectoris, a prevalent sign of coronary artery disease, is recurring bouts of chest pain or suffering that are typically triggered by physical exertion or psychological stress[1,2,3]. This heart condition has significant therapeutic ramifications as it signals the likelihood of adverse cardiovascular events and serves as a sentinel of underlying myocardial ischemia.[4]. To improve patient outcomes and lower associated morbidity and mortality, it is critical to understand the aetiology, clinical manifestation, and management of angina pectoris.[5,6,7].

Historical Context and Signification:

Centuries ago, early medical researchers made significant advances to the diagnosis and treatment of angina pectoris[8,9,10]. Notably, in the late 1700s, William Heberden published a groundbreaking study that offered a thorough clinical definition of angina, defining its key characteristics and setting it apart from other causes of chest pain[11,12,13]. Our knowledge of this illness has grown as a result of later developments in cardiovascular physiology and diagnostic techniques, such as the introduction of electrocardiography and coronary angiography[14,15,16].Given its incidence and prognostic relevance, angina pectoris is of utmost importance in modern cardiology[17,18].Angina acts as a sentinel event in the progression of coronary artery disease. Modifiable risk variables have been identified as important contributors to myocardial infarction, according to epidemiological studies [19,20]. Furthermore, clinical trials like as the CorMicA trial and the Losmapimod trial have expanded our treatment arsenal by providing new insights into innovative pharmacological and interventional approaches for the management of angina[21,22,23,24].

Objective and of the Review:

The goal of this study is to offer a thorough overview of angina pectoris, including information on its pathophysiology, clinical manifestation, diagnostic assessment, and treatment management[25,26,27].

The objectives of this review are as follows:

To Elucidate The Underlying Pathosphysiolocal Mechanism Of Angina Pectoris: We will examine the complex interactions between atherosclerosis, endothelial dysfunction, and myocardial ischemia in the pathophysiology of angina, drawing on foundational works in cardiovascular physiology[26,27,28,29,30].

To delineate the clinical manifestation and diagnostic approach to angina pectoris: We will outline the range of symptoms associated with angina, talk about the usefulness of diagnostic modalities like stress testing and coronary angiography, and highlight new approaches for risk stratification and prognostication, all while incorporating evidence from seminal studies and clinical guidelines[31,32,33,34].

To Review Current Management Strategies For Angina Pectoris: By combining information from meta-analyses and randomised controlled trials, we will assess the safety and effectiveness of invasive procedures, pharmaceutical treatments, and lifestyle changes in the management of angina[17,35,36].

To Explore Emerging Research Trends And Future Directions: We will find promising new treatment targets, diagnostic biomarkers, and personalised techniques for the management of angina pectoris in the future by examining recent developments in basic science and clinical research[37,38,39].

Pathophysiology of Angina Pectoris:

A number of intricately intertwined pathophysiological pathways, chief among them atherosclerosis, coronary artery disease (CAD), and myocardial ischemia, give rise to angina pectoris. Furthermore, a number of risk factors, both modifiable and non-modifiable, contribute to the onset and course of the condition[40,41,42,43].

Atheroclerosis and Coronary Aertery Disease (CAD):

Atherosclerosis is the primary cause of both CAD and angina pectoris. It is characterised by the buildup of plaques that are high in fat within the coronary arteries [445,45,46]. The atherosclerotic process is started by endothelial dysfunction, which is brought on by conditions like inflammation, hypertension, and hyperlipidemia[47,48,49].Plaque formation and coronary artery narrowing result from the subsequent infiltration of lipids, inflammatory cells, and smooth muscle cells, which reduces myocardial perfusion[50,51,52,53,54].

Myocardial Ischemia:Myocardial blood flow is compromised by the increasing blockage of coronary arteries by atherosclerotic plaques, especially during times of elevated oxygen demand (e.g., physical activity)[55,56,57].Myocardial ischemia, which is characterised by insufficient oxygen transport to the myocardium, is the outcome of this supply-demand imbalance[58,59,60].A series of physiological reactions are triggered by ischemia, which include anaerobic metabolism, ATP depletion, and lactate buildup. These reactions culminate in the development of anginal symptoms[61,62,63,64].

Role of Risk Factors:

Hypertension: High elevated blood pressure causes endothelial

dysfunction and promotes atherosclerosis by putting shear stress on arterial walls[65,66,67,68,69,70]. Hypertension increases cardiac stress and oxygen demand, exacerbating myocardial ischemia. [71,72,73].

Hyperlipidemia: Elevated levels of lipoprotein (LDL) cholesterol promote the formation of atherosclerotic plaques within the coronary arteries. [74,75,76]. Lipid deposition causes an inflammatory response that speeds up the growth and instability of plaque and raises the risk of acute coronary syndromes and coronary thrombosis. [77,78,79,80].

Smoking: Tobacco smoke contains numerous toxic substances that accelerate endothelial dysfunction and atherosclerosis. [81,82]. Nicotine tightens coronary arteries, raises heart rate, and amplifies sympathetic tone, all of which worsen myocardial ischemia. [83,84,85,86]. Moreover, smoking promotes accumulation of platelets and thrombosis, which raises the risk of acute coronary syndromes.[87,88].

Clinical Presentation and Diagnosis: Angina pectoris is a malady with specific symptoms that can be identified using a variety of clinical and imaging modalities, including stress examinations, coronary angiography, and imaging methodologies[17,89,90].

Typical symptoms of Angina Pectoris: Usually described as tightness or constriction, angina pectoris manifests as a pressure, squeezing, heaviness, or discomfort in the chest[91,92,93,94]. The drugnitroglycerin can ease these symptoms, which are typically brought on by physical activity, emotional stress, or exposure to cold weather [95].Radiation pain to the neck, jaw, shoulders, arms, or back is another possible symptom for patients. Usually lasting minutes instead of hours, the effects are transient [96,97,98, 99].

Diagnostic Methods:

Stress Testing:

Angina pectoris is frequently diagnosed by stress testing, such as pharmacological stress testing and exercise stress electrocardiography (ECG)[100,101,102,103]. Stress tests, such as pharmacological stress testing and exercise stress electrocardiography (ECG), are commonly used to detect angina pectoris[104,105].In pharmacological stress testing, individuals who are unable to exert themselves physically are given drugs such as dobutamine or adenosine to mimic the effects of exercise[106,107,108,109,110].Unusual ECG results or symptoms during a stressful situation point to myocardial ischemia, which is suggestive of angina[111,112,113,114,115].

Coronary Angiography:

When determining the degree and severity of coronary artery stenosis and diagnosing coronary artery disease, coronary angiography is regarded as the gold standard[116,117,118,119].In order to see the coronary anatomy, a contrast dye is administered through a catheter that is placed into the coronary arteries during this invasive operation[120,121,122].This helps diagnose angina pectoris by identifying coronary artery constriction or obstructive lesions that are symptomatic of atherosclerosis[123,124,125,126].

Imaging Modalities

When a patient has suspected angina pectoris, a number of imaging methods, including nuclear myocardial perfusion imaging (MPI), cardiac magnetic resonance imaging (MRI), and echocardiography, might offer important diagnostic data[127,128].Echocardiography evaluates the shape and function of the heart, whereas cardiac MRI provides a thorough picture of the heart's perfusion and tissue[129,130,131,132,133,134,135].Nuclear MPI detects regions of ischemia or infarction by measuring myocardial perfusion under stress and at rest using radioactive tracers[136,137,138,139].

Management Strategies:

A combination of pharmaceutical therapies, lifestyle changes, and, in certain situations, invasive procedures are used to treat angina [17,140,141]. Here's an outline of management strategies:

1. Pharmacological Interventions:

a. Nitrates: Vasodilators like nitrates help relax and enlarge blood vessels, improving heart blood flow and reducing angina symptoms. Between these prescription drugs is nitroglycerin.[142,143,144,145,146].

b. Beta-Blockers: Beta-blockers, such as metoprolol and atenolol, reduce cardiac workload by blocking the effects of adrenaline. This reduces blood pressure, rhythm, and the quantity of oxygen the heart needs to function.[142,147,148].

c. Calcium Channel Blockers: Calcium channel blockers, which restrict calcium ions from invading the smooth muscle of cardiac and vascular cells, relax and widen blood vessels while putting less strain on the heart. Examples of these blockers include amlodipine and diltiazem.[142,149,150].

d. Antiplatelet Agents: Antiplatelet medications, such as clopidogrel and aspirin, inhibit platelet aggregation and reduce the likelihood of creating blood clots in the coronary arteries, hence lowering the risk of myocardial infarction or unstable angina [142,151,152,153].

2. Lifestyle Modifications:

a. Diet: Maintaining a heart-healthy diet high in fruits, vegetables, whole grains, lean proteins, and low in cholesterol, sodium, and saturated fats can help control angina and lower the risk of cardiovascular events[154,155].

b. Exercise: Under the supervision of a healthcare professional, engaging in regular physical activity can improve cardiovascular fitness, lower blood pressure, lower cholesterol, and improve general wellbeing. Patients should refrain from engaging in any activity that exacerbates their angina[156].

c. Smoking Cessation: For those who suffer from angina, giving up smoking is crucial since it destroys blood vessels, raises the chance of blood clot development, and worsens angina symptoms[157].

3. Invasive Interventions:

a. Angioplasty (Percutaneous Coronary Intervention): By inflating a balloon at the location of the blockage, angioplasty is a minimally invasive technique that opens restricted or blocked coronary arteries. Stent insertion is frequently required to maintain the artery open[158,159,160].

b. Coronary Artery Bypass Grafting (CABG): A healthy artery or vein from another part of the body is utilised during coronary artery bypass grafting (CABG) surgery to open blocked coronary arteries and restore blood flow to the heart muscle[161,162,163].

Variants and Special Considerations:

1. Variant Forms of Angina:

a. Stable Angina: Characterised by consistent chest pain or discomfort that subsides with rest or nitroglycerin, stable angina is brought on by physical exertion or mental stress[164,165,166].It is usually the consequence of fixed stenosis and obstructive coronary artery disease[164,167].

b. Unstable Angina: When compared to stable angina, unstable angina is more severe and typically lasts longer. It is characterised by chest pain or discomfort that happens at rest or with little effort. [92,164,168,169,170]It needs to be treated very away because it could be a warning sign of an imminent heart attack (myocardial infarction)[92,168,169].

c. Microvascular Angina: Despite normal coronary angiography results, microvascular angina, commonly referred to as cardiac syndrome X, is characterised by angina-like chest pain[164,171,172,173].It is thought to be caused by problems with the microvasculature, or tiny blood arteries that nourish the heart muscle[27,174].

2. Angina in Special Populations:

a. Women: Angina in women may present differently than in men, with symptoms such as atypical chest pain, shortness of breath, fatigue, nausea, or abdominal discomfort [175,176,177]. Microvascular angina and non-obstructive coronary artery disease are also more common in women, which might present diagnostic and treatment issues[178,179,180].

b. Elderly: Age-related comorbidities such diabetes, chronic renal disease, and hypertension can exacerbate angina in the senior population[181,182].Because of possible interactions and negative effects, using drugs cautiously may be part of the treatment plan[183].

c. Comorbidities: Individuals who suffer from comorbid conditions such diabetes, hypertension, dyslipidemia, and chronic renal disease may be more susceptible to severe cardiovascular events and angina[184,185,186].To maximise results, management techniques ought to take these comorbid conditions into account[187,188].Understanding and treating angina have advanced recently, with a focus on several important areas:

1. Microvascular Angina: The condition known as microvascular angina, which is brought on by problems with the heart's tiny blood veins, has gained more attention[189,190,191]. Studies have shown how crucial it is to identify and treat microvascular angina because it may go undetected using conventional diagnostic techniques[192]. Researchers are looking into novel treatments that target microvascular dysfunction, such as potassium channel openers and endothelin receptor antagonists[193,194,195,196,197,198].

Precision Medicine: Personalised approaches to treating angina that consider the unique features of each patient, their genetic makeup, and the underlying causes of the condition are gaining popularity[199,200,201,202].

Developments in biomarker research and genetic medicine could result in the creation of customised treatments for particular patient groupings[203,204,205].

Non-invasive Imaging Techniques: The usefulness of non-invasive imaging methods for the diagnosis and risk assessment of angina patients, such as cardiac magnetic resonance imaging (MRI) and cardiac positron emission tomography (PET), is being investigated in ongoing research[206,207,208]. These methods help identify ischemia and direct treatment choices by providing insights into myocardial perfusion, metabolism, and function[209,210,211,212].

Novel Therapies: There is continuing research into novel pharmacological drugs that target various pathways implicated in the pathophysiology of angina[213]. This comprises medications that improve coronary microvascular function, lower inflammation, and increase myocardial oxygen delivery. For instance, ranolazine has demonstrated promise in the treatment of chronic stable angina due to its modulation of cardiac ion channels and enhancement of myocardial oxygen utilisation[214,215,216,217,218,219].

Subjects that need more research include:

Understanding Sex Differences: Men and women may appear with angina differently, as well as react differently to treatment[220,221,222]. To further understand the underlying mechanisms and manage both sexes, more research is required[220,221,222].

Exploring Novel Biomarkers: The discovery of new biomarkers linked to the aetiology and prognosis of angina may enhance risk assessment and direct specialised treatments[223,224,225,226].

Investigating Lifestyle Interventions: Extensive research is being conducted to determine whether particular food patterns, exercise routines, and stress management strategies will lessen angina symptoms and enhance cardiovascular outcomes[160,227,228,229].

CONCLUSION

In short, angina pectoris remains a serious cardiovascular disease with a significant influence on patient morbidity and mortality. Even while our understanding of its pathophysiology and treatment has grown greatly over time, there are still open questions and areas for further research. Recent advances in personalised medicine and our understanding of microvascular angina may enable better angina diagnosis and treatment. Innovative medications and non-invasive imaging technologies are valuable tools for risk assessment and treatment planning. Future research on biomarkers, lifestyle changes, and gender differences will be critical for improving angina treatment options and lowering coronary artery disease rates. Embracing innovative technology and incorporating interdisciplinary techniques can improve patient results and reduce hazards associated with angina pectoris treatment.

REFERENCES

1. DeVon HA, Ryan CJ. Chest pain and associated symptoms of acute coronary syndromes. Journal of Cardiovascular Nursing. 2005 Jul 1;20(4):232-8.
2. Sangvai DG, Rietz AM, Viera AJ. Ischemic Heart Disease. InFamily Medicine: Principles and Practice 2022 Jan 20 (pp. 1055-1063). Cham: Springer International Publishing.
3. Lewis WR, Amsterdam EA. Chest pain. InThe pain management handbook: a concise guide to diagnosis and treatment 1998 (pp. 79-115). Totowa, NJ: Humana Press.
4. Singh S, Loke YK, Spangler JG, Furberg CD. Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis. Cmaj. 2011 Sep 6;183(12):1359-66.
5. Gibbons RJ, Chatterjee K, Daley J, Douglas JS, Fihn SD, Gardin JM, Grunwald MA, Levy D, Lytle BW, O'Rourke RA, Schafer WP. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stable Angina). Journal of the American College of Cardiology. 1999 Jun;33(7):2092-197.
6. Braunwald E, Antman EM, Beasley JW, Califf RM, Cheitlin MD, Hochman JS, Jones RH, Kereiakes D, Kupersmith J, Levin TN, Pepine CJ. ACC/AHA guidelines for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina). Journal of the American College of Cardiology. 2000 Sep;36(3):970-1062.
7. Fernandez SF, Tandar A, Boden WE. Emerging medical treatment for angina pectoris. Expert opinion on emerging drugs. 2010 Jun 1;15(2):283-98.
8. Ryan TJ. The coronary angiogram and its seminal contributions to cardiovascular medicine over five decades. Circulation. 2002 Aug 6;106(6):752-6.
9. Vigliani MB. Keeping a finger on the pulse—a brief history of cardiovascular medicine. InEmerging Technologies for Heart Diseases 2020 Jan 1 (pp. 1-22). Academic Press.
10. Braunwald E. Cardiology: the past, the present, and the future. Journal of the American College of Cardiology. 2003 Dec 17;42(12):2031-41.
11. Tomanek RJ, Tomanek RJ. Historical perspectives. Coronary Vasculature: Development, Structure-Function, and Adaptations. 2013:83-100.
12. White AK. Men making sense of their chest pain. The University of Manchester (United Kingdom); 2000.
13. Armour CM, Allanson JE. Further delineation of cardio-facio-cutaneous syndrome: clinical features of 38 individuals with proven mutations. Journal of medical genetics. 2008 Apr 1;45(4):249-54.
14. Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., ... &Lisheng, L. (2004). Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. The Lancet, 364(9438), 937-952.
15. Rubin GD, Leipsic J, Schoepf UJ, Fleischmann D, Napel S. CT angiography after 20 years: a transformation in cardiovascular disease characterization continues to advance. Radiology. 2014 Jun;271(3):633-52.
16. Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018 Feb 1;104(4):284-92.
17. Ford TJ, Berry C. Angina: contemporary diagnosis and management. Heart. 2020 Mar 1;106(5):387-98.
18. Zahr FE, Mulukutla SR, Marroquin OC. A contemporary overview of the pathophysiology of angina pectoris. Reviews in cardiovascular medicine. 2013 Jan 20;14(S1):3-10.
19. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Investigators IS. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937-52.
20. Ôunpuu S, Negassa A, Yusuf S. INTER-HEART: A global study of risk factors for acute myocardial infarction. American heart journal. 2001 May 1;141(5):711-21.
21. O'Donoghue, M. L., Glaser, R., Cavender, M. A., Aylward, P. E., Bonaca, M. P., Budaj, A. , ... &Braunwald, E. (2017). Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA, 315(15), 1591-1599.
22. McChord J, Hubert A, Bekeredjian R, Ong P. Contemporary pharmacological treatment strategies for patients with angina and unobstructed coronary arteries (ANOCA) due to coronary microvascular dysfunction. Vessel Plus. 2021;5(49):2574-1209.
23. Durante A, Camici PG. Novel insights into an "old" phenomenon: the no reflow. International journal of cardiology. 2015 May 6;187:273-80.
24. Fanaroff AC, Kaltenbach LA, Peterson ED, Hess CN, Cohen DJ, Fonarow GC, Wang TY. Management of Persistent Angina After Myocardial Infarction Treated With Percutaneous Coronary Intervention: Insights From the TRANSLATE ACS Study. Journal of the American Heart Association. 2017 Oct 24;6(10):e007007.
25. Oldroyd, K. G. (2020). Stratified Medical Therapy Using Invasive Coronary Function Testing Ford, T. J., Stanley, B., Good, R., Rocchiccioli, P., McEntegart, M., Watkins, S., ... & in Angina: The CorMicA Trial. JACC: Cardiovascular Interventions, 13(5), 559-570.
26. Schächinger V, Zeiher AM. Atherosclerosis-associated endothelial dysfunction. Zeitschrift für Kardiologie. 2000 Nov;89:IX70-4.
27. Kaski JC, Crea F, Gersh BJ, Camici PG. Reappraisal of ischemic heart disease: fundamental role of coronary microvascular dysfunction in the pathogenesis of angina pectoris. Circulation. 2018 Oct 2;138(14):1463-80.
28. Tousoulis D, Androulakis E, Kontogeorgou A, Papageorgiou N, Charakida M, Siama K, Latsios G, Siasos G, Kampoli AM, Tourikis P, Tsioufis K. Insight to the pathophysiology of stable angina pectoris. Current pharmaceutical design. 2013 Mar 1;19(9):1593-600.
29. Julius BK, Spillmann M, Vassalli G, Villari B, Eberli FR, Hess OM. Angina pectoris in patients with aortic stenosis and normal coronary arteries: mechanisms and pathophysiological concepts. Circulation. 1997 Feb 18;95(4):892-8.
30. Yilmaz A, Sechtem U. Angina pectoris in patients with normal coronary angiograms: current pathophysiological concepts and therapeutic options. Heart. 2012 Jul 1;98(13):1020-9.
31. Kreatsoulas C, Shannon HS, Giacomini M, Velianou JL, Anand SS. Reconstructing angina: cardiac symptoms are the same in women and men. JAMA internal medicine. 2013 May 13;173(9):829-33.
32. Knockaert DC, Buntinx F, Stoens N, Bruyninckx R, Delooz H. Chest pain in the emergency department: the broad spectrum of causes. European Journal of Emergency Medicine. 2002 Mar 1;9(1):25-30.
33. Gibbons RJ. Noninvasive diagnosis and prognosis assessment in chronic coronary artery disease: stress testing with and without imaging perspective. Circulation: Cardiovascular Imaging. 2008 Nov;1(3):257-69.
34. Antonopoulos AS, Angelopoulos A, Tsioufis K, Antoniades C, Tousoulis D. Cardiovascular risk stratification by coronary computed tomography angiography imaging: current state-of-the-art. European journal of preventive cardiology. 2022 Mar 1;29(4):608-24.
35. Thadani U. Management of stable angina–current guidelines: a critical appraisal. Cardiovascular drugs and therapy. 2016 Aug;30:419-26.
36. Authors/Task Force Members, Fox K, Garcia MA, Ardissino D, Buszman P, Camici PG, Crea F, Daly C, De Backer G, Hjemdahl P, Lopez-Sendon J. Guidelines on the management of stable angina pectoris: executive summary: the Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. European heart journal. 2006 Jun 1;27(11):1341-81.
37. Banerjee MN, Bolli R, Hare JM. Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions. Circulation research. 2018 Jul 6;123(2):266-87.
38. Omran F, Kyrou I, Osman F, Lim VG, Randeva HS, Chatha K. Cardiovascular biomarkers: lessons of the past and prospects for the future. International Journal of Molecular Sciences. 2022 May 19;23(10):5680.
39. MacNamara J, Eapen DJ, Quyyumi A, Sperling L. Novel biomarkers for cardiovascular risk assessment: current status and future directions. Future cardiology. 2015 Sep;11(5):597-613.
40. Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868-874.
41. Willerson JT, Armstrong PW. Coronary heart disease syndromes: Pathophysiology and clinical recognition. Coronary artery disease. 2015:365-407.
42. Jinnouchi H, Kolodgie FD, Romero M, Virmani R, Finn AV. Pathophysiology of coronary artery disease. Vessel Based Imaging Techniques: Diagnosis, Treatment, and Prevention. 2020:211-27.
43. Kaski JC. Essentials in stable angina pectoris. Springer; 2016 Aug 15.
44. MA, Dar Mir MA, Qadir A. Exploring the Landscape of Coronary Artery Disease: A Comprehensive Review. American Journal of Biomedicine and Pharmacy. 2024 Mar 16;1(1):9-22.
45. Gaggini M, Gorini F, Vassalle C. Lipids in atherosclerosis: pathophysiology and the role of calculated lipid indices in assessing cardiovascular risk in patients with hyperlipidemia. International journal of molecular sciences. 2022 Dec 21;24(1):75.
46. Selwyn AP, Kinlay S, Libby P, Ganz P. Atherogenic lipids, vascular dysfunction, and clinical signs of ischemic heart disease. Circulation. 1997 Jan 7;95(1):5-7.
47. Poredos P. Endothelial dysfunction in the pathogenesis of atherosclerosis. International Angiology. 2002 Jun 1;21(2):109.
48. Xu S, Ilyas I, Little PJ, Li H, Kamato D, Zheng X, Luo S, Li Z, Liu P, Han J, Harding IC. Endothelial dysfunction in atherosclerotic cardiovascular diseases and beyond: from mechanism to pharmacotherapies. Pharmacological reviews. 2021 Jul 1;73(3):924-67.
49. Mudau M, Genis A, Lochner A, Strijdom H. Endothelial dysfunction: the early predictor of atherosclerosis. Cardiovascular journal of Africa. 2012 May 1;23(4):222-31.
50. Lloyd-Jones, D. M., Larson, M. G., Beiser, A., Levy, D. (1999). Lifetime risk of developing coronary heart disease. The Lancet, 353(9147), 89-92
51. Virmani R, Burke AP, Farb A, Kolodgie FD. Pathology of the vulnerable plaque. Journal of the American College of Cardiology. 2006 Apr 18;47(8S):C13-8.
52. Libby P. Inflammation during the life cycle of the atherosclerotic plaque. Cardiovascular

Research. 2021 Nov 15;117(13):2525-36.
53. Mauriello A, Sangiorgi G, Fratoni S, Palmieri G, Bonanno E, Anemona L, Schwartz RS, Spagnoli LG. Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. Journal of the American College of Cardiology. 2005 May 17;45(10):1585-93.
54. Bentzon JF, Otsuka F, Virmani R, Falk E. Mechanisms of plaque formation and rupture. Circulation research. 2014 Jun 6;114(12):1852-66.
55. Bruning RS, Sturek M. Benefits of exercise training on coronary blood flow in coronary artery disease patients. Progress in cardiovascular diseases. 2015 Mar 1;57(5):443-53.
56. Mir MA, Dar MA, Qadir A. Exploring the Landscape of Coronary Artery Disease: A Comprehensive Review. American Journal of Biomedicine and Pharmacy. 2024 Mar 16;1(1):9-22.
57. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease?. Nature Reviews Cardiology. 2011 Jul;8(7):369-79.
58. De Boer RA, Pinto YM, Van Veldhuisen DJ. The imbalance between oxygen demand and supply as a potential mechanism in the pathophysiology of heart failure: the role of microvascular growth and abnormalities. Microcirculation. 2003 Jan 1;10(2):113-26.
59. Heusch G. Myocardial ischemia: lack of coronary blood flow, myocardial oxygen supply-demand imbalance, or what?. American Journal of Physiology-Heart and Circulatory Physiology. 2019 Jun 1;316(6):H1439-46.
60. Mihatov N, Januzzi Jr JL, Gaggin HK. Type 2 myocardial infarction due to supply–demand mismatch. Trends in cardiovascular medicine. 2017 Aug 1;27(6):408-17.
61. Ambrose, J. A., & Singh, M. (2000). Pathophysiology of coronary artery disease leading to acute coronary syndromes. Funded Access, 96(5), 15-20.
62. Annachhatre AS, Annachhatre SR. Preconditioning in cardiac anesthesia…… where are we?. Annals of Cardiac Anaesthesia. 2019 Oct 1;22(4):412-21.
63. Vishwakarma VK, Upadhyay PK, Gupta JK, Yadav HN. Pathophysiologic role of ischemia reperfusion injury: A review. Journal of Indian College of Cardiology. 2017 Sep 1;7(3):97-104.
64. Fathima SN. An Update on Myocardial Infarction. Current Research and Trends in Medical Science and Technology. 2021;1.
65. Gielen, S., Schuler, G., Adams, V. (2010). Cardiovascular effects of exercise training. Circulation, 122(12), 1221-1238.
66. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in atherosclerosis. Jama. 1999 Dec 1;282(21):2035-42.
67. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. Journal of vascular research. 1996 Sep 24;33(3):181-94.
68. Chiu JJ, Usami S, Chien S. Vascular endothelial responses to altered shear stress: pathologic implications for atherosclerosis. Annals of medicine. 2009 Jan 1;41(1):19-28.
69. Ferroni P, Basili S, Paoletti V, Davi G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutrition, metabolism and cardiovascular diseases. 2006 Apr 1;16(3):222-33.
70. Konukoglu D, Uzun H. Endothelial dysfunction and hypertension. Hypertension: from basic research to clinical practice. 2017:511-40.
71. Murphy BP, Stanton T, Dunn FG. Hypertension and myocardial ischemia. Medical Clinics of North America. 2009 May 1;93(3):681-95.
72. Robertson CS, Clifton G AA, Grossman RG. Treatment of hypertension with head injury. Journal neurosurgery. 59(3):455-60.
73. Ruffolo RR, Feuerstein GZ. Pharmacology of carvedilol: rationale for use in hypertension, coronary artery disease, and congestive heart failure. Cardiovascular drugs and therapy. 1997 May;11:247-56.
74. Grundy SM. Role of low-density lipoproteins in atherogenesis and development of coronary heart disease. Clinical chemistry. 1995 Jan 1;41(1):139-46.
75. Kimura T, Itoh T, Fusazaki T, Matsui H, Sugawara S, Ogino Y, Endo H, Kobayashi K, Nakamura M. Low-Density Lipoprotein-Cholesterol/High-Density Lipoprotein-Cholesterol Ratio Predicts Lipid-Rich Coronary Plaque in Patients With Coronary Artery Disease–Integrated-Backscatter Intravascular Ultrasound Study–. Circulation Journal. 2010;74(7):1392-8.
76. Nishikura T, Koba S, Yokota Y, Hirano T, Tsunoda F, Shoji M, Hamazaki Y, Suzuki H, Itoh Y, Katagiri T, Kobayashi Y. Elevated small dense low-density lipoprotein cholesterol as a predictor for future cardiovascular events in patients with stable coronary artery disease. Journal of atherosclerosis and thrombosis. 2014 Aug 26;21(8):755-67.
77. Shah PK. Inflammation and plaque vulnerability. Cardiovascular drugs and therapy. 2009 Feb;23:31-40.
78. Corti R, Hutter R, Badimon JJ, Fuster V. Evolving concepts in the triad of atherosclerosis, inflammation and thrombosis. Journal of thrombosis and thrombolysis. 2004 Feb;17:35-44.
79. AP, Falk E. Vulnerable and dangerous coronary plaques. Atherosclerosis. 1995 Dec 1;118:S141-9. Schroeder
80. Shah PK. Plaque disruption and thrombosis: potential role of inflammation and infection. Cardiology in review. 2000 Jan 1;8(1):31-9
81. Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arteriosclerosis, thrombosis, and vascular biology. 2014 Mar;34(3):509-15.
82. Siasos G, Tsigkou V, Kokkou E, Oikonomou E, Vavuranakis M, Vlachopoulos C, Verveniotis A, Limperi M, Genimata V, G Papavassiliou A, Stefanadis C. Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. Current medicinal chemistry. 2014 Nov 1;21(34):3936-48.
83. Hanna ST. Nicotine effect on cardiovascular system and ion channels. Journal of cardiovascular pharmacology. 2006 Mar 1;47(3):348-58.
84. Khosla S, Laddu A, Ehrenpreis S, Somberg JC. Cardiovascular effects of nicotine: relation to deleterious effects of cigarette smoking. American heart journal. 1994 Jun 1;127(6):1669-72.
85. Kaijser L, Berglund B. Effect of nicotine on coronary bloodflow in man. Clinical Physiology. 1985 Dec;5(6):541-52.
86. Sedehi D, Cigarroa JE. Precipitants of myocardial ischemia. Chronic coronary artery disease: a companion to Braunwald's heart disease. 2017 Jan 1;69.
87. Hung J, Lam JY, Lacoste L, Letchacovski G. Cigarette smoking acutely increases platelet thrombus formation in patients with coronary artery disease taking aspirin. Circulation. 1995 Nov 1;92(9):2432-6.
88. Barua RS, Ambrose JA. Mechanisms of coronary thrombosis in cigarette smoke exposure. Arteriosclerosis, thrombosis, and vascular biology. 2013 Jul;33(7):1460-7.
89. Nakas G, Bechlioulis A, Marini A, Vakalis K, Bougiakli M, Giannitsi S, Nikolaou K, Antoniadou EI, Kotsia A, Gartzonika K, Chasiotis G. The importance of characteristics of angina symptoms for the prediction of coronary artery disease in a cohort of stable patients in the modern era. Hellenic Journal of Cardiology. 2019 Jul 1;60(4):241-6.
90. J, Henzler T, Sueselbeck T, Fink C, Borggrefe M, Walter T. Clinical assessment of chest pain and Gruettner guidelines for imaging. European Journal of Radiology. 2012 Dec 1;81(12):3663-8.
91. Crea F, Gaspardone A. New look to an old symptom: angina pectoris. Circulation. 1997 Nov 18;96(10):3766-73.
92. Peate I. Angina–management of chest pain. British Journal of Healthcare Assistants. 2022 Mar 2;16(3):110-5.
93. Paswan S, Sharma RK, Gaur AR, Sachan A, Yadav MS, Sharma P, Gautam M. Angina pectoris epidemic in India: a comprehensive review of clinical features, differential diagnosis, and remedies. Ind. J. Res. Pharm. & Biotech. 2013 May 1;1(3):339-45.
94. Davis D. Differential diagnosis of chest pain. Disease-a-Month. 1958 Feb 1;4(2):1-59.
95. EUROPEAN JOURNAL OF MODERN MEDICINE AND PRACTICE. 2023 Dec 10;3(12):81-7. Komilovich EB. Coronary Artery Diseas
96. Mieres, J. H., Shaw, L. J., Arai, A., Budoff, M. J., Flamm, S. D., Hundley, W. G., ... & Vogel-Claussen, J. (2019). Role of noninvasive testing in the clinical evaluation of women with suspected ischemic heart disease: a consensus statement from the American Heart Association. Circulation, 139(10), e1114-e1135
97. Kucia AM, Beltrame JF, Keenan J. Chest Pain Assessment. Cardiac Care: A Practical Guide for Nurses. 2022 Aug 26:216-30.
98. Simon A. Chest pain. InTintinalli's emergency medicine: a comprehensive study guide 2016. McGraw-Hill, New York, NY.
99. Sabatine MS, Cannon CP. Approach to the patient with chest pain. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 9th ed. Philadelphia, PA: Elsevier/Saunders. Doddridge N. Chest Pain–Cardiac. Emergency Differential Diagnosis. 2009:9.
100. Banerjee A, Newman DR, Van den Bruel A, Heneghan C. Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and metaanalysis of prospective studies. International journal of clinical practice. 2012 May;66(5):477-92.
101. San Roman JA, Vilacosta I, Castillo JA, Rollan MJ, Hernández M, Peral V, Garcimartin I, de la Torre MD, Fernandez-Aviles F. Selection of the optimal stress test for the diagnosis of coronary artery disease. Heart. 1998 Oct 1;80(4):370-6.
102. Lear SA, Brozic A, Myers JN, Ignaszewski A. Exercise stress testing: an overview of current guidelines. Sports Medicine. 1999 May;27:285-312.
103. Sharif S, Alway SE. The diagnostic value of exercise stress testing for cardiovascular disease is more than just st segment changes: A review. J IntegrCardiol. 2016;2(4):341-55.
104. Faris JV, McHenry PL, Morris SN. Concepts and applications of treadmill exercise testing and the exercise electrocardiogram. American Heart Journal. 1978 Jan 1;95(1):102-14.
105. Hughes JW, Casey E, Luyster F, Doe VH, Waechter D, Rosneck J, Josephson R. Depression symptoms predict heart rate recovery after treadmill stress testing. American heart journal. 2006 May 1;151(5):1122-e1.
106. Cotrado AY, dos Santos Ker W. Exercise and Pharmacologic Stress Testing. Nuclear Cardiology: Basic and Advanced Concepts in Clinical Practice. 2021:517-44.
107. ZOGHBI GJ, ISKANDRIAN A. Pharmacological stress testing 16. Nuclear cardiac imaging: Principles and applications. 2008 Sep 25:293.
108. Gupta A, Zoghbi GJ, Hage FG. Pharmacologic stress testing. InPrinciples and Applications: Nuclear Cardiac Imaging 2015 Oct 22 (p. 196). Oxford: Oxford University Press.
109. Dilsizian V, Gewirtz H, Paivanas N, Kitsiou AN, Hage FG, Crone NE, Schwartz RG. Serious and potentially life threatening complications of cardiac stress testing: Physiological mechanisms and management strategies. Journal of Nuclear Cardiology. 2015 Dec;22:1198-213.
110. Miller DD. Physiologic and pharmacologic stressors. Atlas of Nuclear Cardiology. 2021:125-60.
111. Fihn, S. D., Blankenship, J. C., Alexander, K. P., Bittl, J. A., Byrne, J. G., Fletcher, B. J., ... & Williams, D. O. (2014). 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 64(18), 1929-1949.
112. Cecchi AC, Dovellini EV, Marchi F, Pucci P, Santoro GM, Fazzini PF. Silent myocardial ischemia during ambulatory electrocardiographic monitoring in patients with effort angina. Journal of the American College of Cardiology. 1983 Mar 1;1(3):934-9.
113. Jiang W, Samad Z, Boyle S, Becker RC, Williams R, Kuhn C, Ortel TL, Rogers J, Kuchibhatla M, O'Connor C, Velazquez EJ. Prevalence and clinical characteristics of mental stress–induced myocardial ischemia in patients with coronary heart disease. Journal of the American College of Cardiology. 2013 Feb 19;61(7):714-22.
114. Stepanovic J, Ostojic M, Beleslin B, Vukovic O, Dikic AD, Giga V, Nedeljkovic I, Nedeljkovic M, Stojkovic S, Vukcevic V, Dobric M. Mental stress–induced ischemia in patients with coronary artery disease: echocardiographic characteristics and relation to exercise-induced ischemia. Psychosomatic medicine. 2012 Sep 1;74(7):766-72.
115. Levy BI, Heusch G, Camici PG. The many faces of myocardial ischaemia and angina. Cardiovascular research. 2019 Aug 1;115(10):1460-70.
116. Jiangping S, Zhe Z, Wei W, Yunhu S, Jie H, Hongyue W, Hong Z, Shengshou H. Assessment of coronary artery stenosis by coronary angiography: a head-to-head comparison with pathological coronary artery anatomy. Circulation: Cardiovascular Interventions. 2013 Jun;6(3):262-8.
117. E, Weigold G, Fuisz A, Weissman NJ. New imaging techniques for diagnosing coronary artery disease. Cmaj. 2006 Escolar Feb 14;174(4):487-95.
118. Mowatt G, Cook JA, Hillis GS, Walker S, Fraser C, Jia X, Waugh N. 64-Slice computed tomography angiography in the diagnosis and assessment of coronary artery disease: systematic review and meta-analysis. Heart. 2008 Nov 1;94(11):1386-93.
119. Van Velzen JE, Schuijf JD, de Graaf FR, Boersma E, Pundziute G, Spanó F, Boogers MJ, Schalij MJ, Kroft LJ, de Roos A, Jukema JW. Diagnostic performance of non-invasive multidetector computed tomography coronary angiography to detect coronary artery disease using different endpoints: detection of significant stenosis vs. detection of atherosclerosis. European heart journal. 2011 Mar 1;32(5):637-45.
120. Dotter CT, Frische LH. Visualization of the coronary circulation by occlusion aortography: a practical method. Radiology. 1958 Oct;71(4):502-24.
121. Conti CR. Coronary arteriography. Circulation. 1977 Feb;55(2):227-37.
122. Van de Veire NR, Schuijf JD, De Sutter J, Devos D, Bleeker GB, De Roos A, Van der Wall EE, Schalij MJ, Bax JJ. Non-invasive visualization of the cardiac venous system in coronary artery disease patients using 64-slice computed tomography. Journal of the American College of Cardiology. 2006 Nov 7;48(9):1832-8.
123. Patel, M. R., Peterson, E. D., Dai, D., Brennan, J. M., Redberg, R. F., Anderson, H. V., ... & Brindis, R. G. (2010). Low diagnostic yield of elective coronary angiography. New England Journal of Medicine, 362(10), 886-895.
124. Kanaganayagam GS, Ngo AT, Alsafi A, Kamanahalli R, Sutaria N, Mittal T, Ariff B. CT coronary angiography in the investigation of chest pain—beyond coronary artery atherosclerosis; a pictorial review. International journal of cardiology. 2014 Oct 20;176(3):618-29.
125. Beck S, Pereyra VM, Seitz A, McChord J, Hubert A, Bekeredjian R, Sechtem U, Ong P. Invasive diagnosis of coronary functional disorders causing angina pectoris. European Cardiology Review. 2021 Feb;16.
126. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008 Feb 21;451(7181):953-7.

127. Mangla A, Oliveros E, Williams Sr KA, Kalra DK. Cardiac imaging in the diagnosis of coronary artery disease. Current problems in cardiology. 2017 Oct 1;42(10):316-66.
128. Xaplanteris P. Angina pectoris: non-invasive methods in the diagnosis and follow-up. Кардиология: отнауки к практике. 2017(2):70-81.
129. Palmieri V, Dahlöf B, DeQuattro V, Sharpe N, Bella JN, de Simone G, Paranicas M, Fishman D, Devereux RB. Reliability of echocardiographic assessment of left ventricular structure and function: the PRESERVE study. Journal of the American College of Cardiology. 1999 Nov 1;34(5):1625-32.
130. Savage DD, Drayer JI, Henry WL, Mathews Jr EC, Ware JH, Gardin JM, Cohen ER, Epstein SE, Laragh JH. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation. 1979 Apr;59(4):623-32.
131. Peterson LR, Waggoner AD, Schechtman KB, Meyer T, Gropler RJ, Barzilai B, Dávila-Román VG. Alterations in left ventricular structure and function in young healthy obese women: assessment by echocardiography and tissue Doppler imaging. Journal of the American College of Cardiology. 2004 Apr 21;43(8):1399-404.
132. Coelho-Filho OR, Rickers C, Kwong RY, Jerosch-Herold M. MR myocardial perfusion imaging. Radiology. 2013 Mar;266(3):701-15.
133. Beijnink CW, van der Hoeven NW, Konijnenberg LS, Kim RJ, Bekkers SC, Kloner RA, Everaars H, El Messaoudi S, van Rossum AC, van Royen N, Nijveldt R. Cardiac MRI to visualize myocardial damage after ST-segment elevation myocardial infarction: a review of its histologic validation. Radiology. 2021 Oct;301(1):4-18.
134. Saeed M, Van TA, Krug R, Hetts SW, Wilson MW. Cardiac MR imaging: current status and future direction. Cardiovascular diagnosis and therapy. 2015 Aug;5(4):290.
135. Blankstein R, Di Carli MF. Integration of coronary anatomy and myocardial perfusion imaging. Nature Reviews Cardiology. 2010 Apr;7(4):226-36.
136. Montalescot, G., Sechtem, U., Achenbach, S., Andreotti, F., Arden, C., Budaj, A., ... &Knuuti, J. (2013). 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. European Heart Journal, 34(38), 2949-3003.
137. Bourque JM, Beller GA. Stress myocardial perfusion imaging for assessing prognosis: an update. JACC: Cardiovascular Imaging. 2011 Dec;4(12):1305-19.
138. Ora M, Gambhir S. Myocardial perfusion imaging: a brief review of nuclear and nonnuclear techniques and comparative evaluation of recent advances. Indian Journal of Nuclear Medicine. 2019 Oct 1;34(4):263-70.
139. Chetrit M, Verma BR, Xu B. Choosing the appropriate stress test for myocardial perfusion imaging. Current Cardiovascular Imaging Reports. 2019 Apr;12:1-2.
140. Trujillo TC, Dobesh PP. Traditional management of chronic stable angina. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2007 Dec;27(12):1677-91.
141. RA, O'Flynn N. Management of stable angina: summary of NICE guidance. Heart. 2012 Henderson Mar 15;98(6):500-7.
142. Amsterdam EA, Wenger NK, Brindis RG, et al. 2014 AHA/ACC guideline for the management of patients with non–ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64(24):e139-e228.
143. Abrams J. Beneficial actions of nitrates in cardiovascular disease. The American journal of cardiology. 1996 May 30;77(13):C31-7.
144. McGregor M. The nitrates and myocardial ischemia. Circulation. 1982 Oct;66(4):689-92.
145. JC, Feelisch M, Horowitz JD, Frenneaux MP, Madhani M. Pharmacology and therapeutic role of Bailey inorganic nitrite and nitrate in vasodilatation. Pharmacology & therapeutics. 2014 Dec 1;144(3):303-20.
146. Patra S, Gupta P, Kumari R, Jana S, Haldar PK, Bhowmik R, Mandal A, Shaharyar MA, Mazumdar H, Anand K, Karmakar S. Insights into the mode of action of antianginal and vasodilating agents. InHow Synthetic Drugs Work 2023 Jan 1 (pp. 329-348). Academic Press.
147. Bangalore S, Messerli FH, Kostis JB, Pepine CJ. Cardiovascular protection using beta-blockers: a critical review of the evidence. Journal of the American College of Cardiology. 2007 Aug 14;50(7):563-72.
148. Martinez A, Lakkimsetti M, Maharjan S, Aslam MA, Basnyat A, Kafley S, saketh Reddy S, Ahmed SS, Razzaq W, Adusumilli S, Khawaja UA. Beta-Blockers and Their Current Role in Maternal and Neonatal Health: A Narrative Review of the Literature. Cureus. 2023 Aug 24;15(8).
149. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. Journal of cardiovascular pharmacology and therapeutics. 2014 Nov;19(6):501-15.
150. Adams J, Khan E. Medications Used for the Cardiovascular System. Understanding Pharmacology in Nursing Practice. 2020:167-217.
151. Moshfegh K, Redondo M, Julmy F, Wuillemin WA, Gebauer MU, Haeberli A, Meyer BJ. Antiplatelet effects of clopidogrel compared with aspirin after myocardial infarction: enhanced inhibitory effects of combination therapy. Journal of the American College of Cardiology. 2000 Sep;36(3):699-705..
152. Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. Journal of the American College of Cardiology. 2017 Oct 3;70(14):1760-76.
153. Schafer AI. Antiplatelet therapy. The American journal of medicine. 1996 Aug 1; 101(2):199-209.
154. Honda M. Reverse Heart Disease Naturally: Cures for high cholesterol, hypertension, arteriosclerosis, blood clots, aneurysms, myocardial infarcts and more. Hatherleigh Press; 2019 Mar 26.
155. Mitra A, Pradhan R, Mukherjee S. Importance of heart-healthy diet. Journal of Human Ecology. 2009 Jul 1;27(1):53-61.
156. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381
157. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J. 2016;37(29):2315-2381.
158. Samuel PO, Edo GI, Emakpor OL, Oloni GO, Ezekiel GO, Essaghah AE, Agoh E, Agbo JJ. Lifestyle modifications for preventing and managing cardiovascular diseases. Sport Sciences for Health. 2024 Mar;20(1):23-36.
159. Sapp PA, Riley TM, Tindall AM, Sullivan VK, Johnston EA, Petersen KS, Kris-Etherton PM. Nutrition and atherosclerotic cardiovascular disease. InPresent Knowledge in Nutrition 2020 Jan 1 (pp. 393-411). Academic Press.
160. Zarraga IG, Schwarz ER. Impact of dietary patterns and interventions on cardiovascular health. Circulation. 2006 Aug 29;114(9):961-73.
161. Kulik A, Ruel M, Jneid H, Ferguson TB, Hiratzka LF, Ikonomidis JS, Lopez-Jimenez F, McNallan SM, Patel M, Roger VL, Sellke FW. Secondary prevention after coronary artery bypass graft surgery: a scientific statement from the American Heart Association. Circulation. 2015 Mar 10;131(10):927-64.
162. Pooria A, Pourya A, Gheini A. Postoperative complications associated with coronary artery bypass graft surgery and their therapeutic interventions. Future Cardiology. 2020 Apr;16(5):481-96.
163. Jowett NI, Thompson DR. Comprehensive coronary care. Elsevier Health Sciences; 2007 May 7.
164. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
165. Abrams J. Chronic stable angina. New England Journal of Medicine. 2005 Jun 16;352(24):2524-33.
166. Krishnaswamy A, Kapadia SR. Stable angina. Manual of cardiovascular medicine. 2012 Sep 26;3:77-100.
167. Reeh J, Therming CB, Heitmann M, Højberg S, Sørum C, Bech J, Husum D, Dominguez H, Sehestedt T, Hermann T, Hansen KW. Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina. European heart journal. 2019 May 7;40(18):1426-35.
168. Fulton M, Lutz W, Donald KW, Kirby BJ, Duncan B, Morrison SL, Kerr F, Julian DG, Oliver MF. Natural history of unstable angina. The Lancet. 1972 Apr 22;299(7756):860-5.
169. Lu L, Liu M, Sun R, Zheng Y, Zhang P. Myocardial infarction: symptoms and treatments. Cell biochemistry and biophysics. 2015 Jul;72:865-7.
170. Cairns JA, Fantus IG, Klassen GA. Unstable angina pectoris. American Heart Journal. 1976 Sep 1;92(3):373-86.
171. Jarczewski J, Jarczewska A, Boryczko A, Poniatowski A, Furgała A, Surdacki A, Gil K. Microvascular angina (Cardiac Syndrome X) from a historical overview, epidemiology, pathophysiology to treatment recommendations—a minireview. Folia Medica Cracoviensia. 2021;61(3).
172. Kaski JC. Cardiac syndrome X and microvascular angina. InChest pain with normal coronary angiograms: pathogenesis, diagnosis and management 1999 Feb 28 (pp. 1-12). Boston, MA: Springer US.
173. Beltrame JF. Advances in understanding the mechanisms of angina pectoris in cardiac syndrome X. European heart journal. 2005 May 1;26(10):946-8.
174. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010 Jun 1;121(21):2317-25.
175. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009;54(17):1561-1575
176. Caldwell MA, Miaskowski C. The symptom experience of angina in women. Pain management nursing. 2000 Sep 1;1(3):69-78.
177. DeVon HA, Zerwic JJ. Symptoms of acute coronary syndromes: are there gender differences? A review of the literature. Heart & Lung. 2002 Jul 1;31(4):235-45.
178. Shaw LJ, Bugiardini R, Merz CN. Women and ischemic heart disease: evolving knowledge. J Am Coll Cardiol. 2009;54(17):1561-1575. DOI: 10.1016/j.jacc.2009.04.098
179. Waheed N, Elias-Smale S, Malas W, Maas AH, Sedlak TL, Tremmel J, Mehta PK. Sex differences in non-obstructive coronary artery disease. Cardiovascular research. 2020 Mar 1;116(4):829-40.
180. Banks K, Lo M, Khera A. Angina in women without obstructive coronary artery disease. Current cardiology reviews. 2010 Feb 1;6(1):71-81.
181. Gadó K, Szabo A, Markovics D, Virág A. Most common cardiovascular diseases of the elderly–A review article. Developments in Health Sciences. 2022 Mar 16;4(2):27-32.
182. Nanna MG, Wang SY, Damluji AA. Management of stable angina in the older adult population. Circulation: Cardiovascular Interventions. 2023 Apr;16(4):e012438.
183. Knuuti J, Wijns W, Saraste A, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407-477.
184. Van Der Zee S, Baber U, Elmariah S, Winston J, Fuster V. Cardiovascular risk factors in patients with chronic kidney disease. Nature Reviews Cardiology. 2009 Sep;6(9):580-9.
185. Go AS, Bansal N, Chandra M, Lathon PV, Fortmann SP, Iribarren C, Hsu CY, Hlatky MA, ADVANCE Study Investigators. Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease. Journal of the American College of Cardiology. 2011 Oct 4;58(15):1600-7.
186. Herzog CA, Asinger RW, Berger AK, Charytan DM, Díez J, Hart RG, Eckardt KU, Kasiske BL, McCullough PA, Passman RS, DeLoach SS. Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney international. 2011 Sep 2;80(6):572-86.
187. Joshi PH, De Lemos JA. Diagnosis and management of stable angina: a review. Jama. 2021 May 4;325(17):1765-78.
188. Fihn SD, Williams SV, Daley J, Gibbons RJ. Guidelines for the management of patients with chronic stable angina: treatment. Annals of internal medicine. 2001 Oct 16;135(8_Part_1):616-32.
189. Yuhua S, Baoping W. Coronary Microvascular Dysfunction and Microvascular Angina. International Journal of Cardiovascular Practice. 2019 Jul 31;4(3):62-8.
190. Park JJ, Park SJ, Choi DJ. Microvascular angina: angina that predominantly affects women. The Korean journal of internal medicine. 2015 Mar;30(2):140.
191. Vancheri F, Longo G, Vancheri S, Henein M. Coronary microvascular dysfunction. Journal of Clinical Medicine. 2020 Sep 6;9(9):2880.
192. Titterington JS, Hung OY, Wenger NK. Microvascular angina: an update on diagnosis and treatment. Future Cardiology. 2015 Mar;11(2):229-42.
193. Dzau VJ, Ginsburg GS. Realizing the Full Potential of Precision Medicine in Health and Health Care. JAMA. 2016
194. Tousoulis D, Simopoulou C, Papageorgiou N, Oikonomou E, Hatzis G, Siasos G, Tsiamis E, Stefanadis C. Endothelial dysfunction in conduit arteries and in microcirculation. Novel therapeutic approaches. Pharmacology & therapeutics. 2014 Dec 1;144(3):253-67.
195. Wang H, Long C, Duan Z, Shi C, Jia G, Zhang Y. A new ATP-sensitive potassium channel opener protects endothelial function in cultured aortic endothelial cells. Cardiovascular research. 2007 Feb 1;73(3):497-503.
196. Sobey CG. Potassium channel function in vascular disease. Arteriosclerosis, thrombosis, and vascular biology. 2001 Jan;21(1):28-38.
197. Jensen BS, Strobaek D, Olesen S, Christophensen P. The Ca2+-activated K+ channel of intermediate conductance: a molecular target for novel treatments?. Current Drug Targets. 2001 Dec 1;2(4):401-22.
198. Enevoldsen FC, Sahana J, Wehland M, Grimm D, Infanger M, Krüger M. Endothelin receptor antagonists: status quo and future perspectives for targeted therapy. Journal of clinical medicine. 2020 Mar 18;9(3):824.
199. Infante T, Del Viscovo L, De Rimini ML, Padula S, Caso P, Napoli C. Network medicine: a clinical approach for precision medicine and personalized therapy in coronary heart disease. Journal of Atherosclerosis and Thrombosis. 2020 Apr 1;27(4):279-302.
200. Johnson JA, Cavallari LH. Pharmacogenetics and cardiovascular disease—implications for personalized medicine. Pharmacological reviews. 2013 Jul 1;65(3):987-1009.
201. Crea F, Libby P. Acute coronary syndromes: the way forward from mechanisms to precision treatment. Circulation. 2017 Sep 19;136(12):1155-66.
202. Ginsburg GS, Donahue MP, Newby LK. Prospects for personalized cardiovascular medicine: the impact of genomics. Journal of the American College of Cardiology. 2005

Nov 1;46(9):1615-27.
203. La Thangue NB, Kerr DJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nature reviews Clinical oncology. 2011 Oct;8(10):587-96.
204. Wang RC, Wang Z. Precision medicine: Disease subtyping and tailored treatment. Cancers. 2023 Jul 28;15(15):3837.
205. Kalia M. Biomarkers for personalized oncology: recent advances and future challenges. Metabolism. 2015 Mar 1;64(3):S16-21.
206. Jaarsma C, Leiner T, Bekkers SC, Crijns HJ, Wildberger JE, Nagel E, Nelemans PJ, Schalla S. Diagnostic performance of noninvasive myocardial perfusion imaging using single-photon emission computed tomography, cardiac magnetic resonance, and positron emission tomography imaging for the detection of obstructive coronary artery disease: a meta-analysis. Journal of the American College of Cardiology. 2012 May 8;59(19):1719-28.
207. Kazakauskaitė E, Žaliaduonytė-Pekšienė D, Rumbinaitė E, Keršulis J, Kulakienė I, Jurkevičius R. Positron emission tomography in the diagnosis and management of coronary artery disease. Medicina. 2018 Jul 11;54(3):47.
208. Tarkin JM, Ćorović A, Wall C, Gopalan D, Rudd JH. Positron emission tomography imaging in cardiovascular disease. Heart. 2020 Nov 1;106(22):1712-8.
209. Douglas, P.S., Berman, D.S., Cerqueira, M.D., Chinnaiyan, K., Cohen, M.S., Lundbye, J.B., … & Woodard, P.K. (2016). The Future of Cardiac Imaging: Report of a Think Tank Convened by the American College of Cardiology. Journal of the American College of Cardiology, 67(8), 1019-1030
210. Dewey M, Siebes M, Kachelrieß M, Kofoed KF, Maurovich-Horvat P, Nikolaou K, Bai W, Kofler A, Manka R, Kozerke S, Chiribiri A. Clinical quantitative cardiac imaging for the assessment of myocardial ischaemia. Nature Reviews Cardiology. 2020 Jul;17(7):427-50.
211. Shehata ML, Basha TA, Hayeri MR, Hartung D, Teytelboym OM, Vogel-Claussen J. MR myocardial perfusion imaging: insights on techniques, analysis, interpretation, and findings. Radiographics. 2014 Oct;34(6):1636-57.
212. Katikireddy CK, Mann N, Brown D, Van Tosh A, Stergiopoulos K. Evaluation of myocardial ischemia and viability by noninvasive cardiac imaging. Expert review of cardiovascular therapy. 2012 Jan 1;10(1):55-73.
213. Kottoor SJ, Arora RR. The utility of anti-inflammatory agents in cardiovascular disease: a novel perspective on the treatment of atherosclerosis. Journal of cardiovascular pharmacology and therapeutics. 2018 Nov;23(6):483-93.
214. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. JAMA. 2007;297(16):1775-1783
215. Cattaneo M, Porretta AP, Gallino A. Ranolazine: drug overview and possible role in primary microvascular angina management. International journal of cardiology. 2015 Feb 15;181:376-81.
216. Kaplan A, Amin G, Abidi E, Altara R, Booz GW, Zouein FA. Role of ranolazine in heart failure: From cellular to clinic perspective. European journal of pharmacology. 2022 Mar 15;919:174787.
217. Sharp RP, Patatanian E, Sirajuddin R. Use of ranolazine for the treatment of coronary microvascular dysfunction. American Journal of Cardiovascular Drugs. 2021 Sep;21:513-21.
218. Pratiti R, Sud P, Yousef M, Moza A. Cardiovascular Effects of Ranolazine and the Scope for Translational Research: A Current Review of Literature. Frontiers in Cardiovascular Drug Discovery: Volume 6. 2022 Nov 11;6:1-53.
219. Nusca A, Bernardini F, Mangiacapra F, Maddaloni E, Melfi R, Ricottini E, Piccirillo F, Manfrini S, Ussia GP, Grigioni F. Ranolazine Improves Glycemic Variability and Endothelial Function in Patients with Diabetes and Chronic Coronary Syndromes: Results from an Experimental Study. Journal of diabetes research. 2021 Dec 31;2021.
220. Daly C, Clemens F, Lopez Sendon JL, Tavazzi L, Boersma E, Danchin N, Delahaye F, Gitt A, Julian D, Mulcahy D, Ruzyllo W. Gender differences in the management and clinical outcome of stable angina. Circulation. 2006 Jan 31;113(4):490-8.
221. Hemingway H, McCallum A, Shipley M, Manderbacka K, Martikainen P, Keskimäki I. Incidence and prognostic implications of stable angina pectoris among women and men. Jama. 2006 Mar 22;295(12):1404-11.
222. Goldberg RJ, Goff D, Cooper L, Luepker R, Zapka J, Bittner V, Osganian S, Lessard D, Cornell C, Meshack A, Mann C. Age and sex differences in presentation of symptoms among patients with acute coronary disease: the REACT trial. Coronary artery disease. 2000 Jul 1;11(5):399-407.
223. Lyngbakken MN, Myhre PL, Røsjø H, Omland T. Novel biomarkers of cardiovascular disease: applications in clinical practice. Critical reviews in clinical laboratory sciences. 2019 Jan 2;56(1):33-60.
224. Wang J, Tan GJ, Han LN, Bai YY, He M, Liu HB. Novel biomarkers for cardiovascular risk prediction. Journal of geriatric cardiology: JGC. 2017 Feb;14(2):135.
225. Razzouk L, Fusaro M, Esquitin R. Novel biomarkers for risk stratification and identification of lifethreatening cardiovascular disease: troponin and beyond. Current cardiology reviews. 2012 May 1;8(2):109-15.
226. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. American heart journal. 2010 Oct 1;160(4):583-94.
227. Schuler GE, Schlierf GU, Wirth AL, Mautner HP, Scheurlen HA, Thumm MI, Roth HA, Schwarz FR, Kohlmeier MA, Mehmel HC. Low-fat diet and regular, supervised physical exercise in patients with symptomatic coronary artery disease: reduction of stress-induced myocardial ischemia. Circulation. 1988 Jan;77(1):172-81.
228. Kerley CP. Dietary patterns and components to prevent and treat heart failure: a comprehensive review of human studies. Nutrition research reviews. 2019 Jun;32(1):1-27.
229. Miller NH, Taylor CB. Lifestyle management for patients with coronary heart disease. Human Kinetics; 1995.